-
Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET
-
Enanta Pharmaceuticals (ENTA) PT Lowered to $88 at RBC Capital
-
Enanta Pharmaceuticals (ENTA) PT Raised to $98 at RBC Capital
-
Enanta Pharmaceuticals to Present at Upcoming Investor Conference
-
Enanta Pharmaceuticals (ENTA) PT Lowered to $94 at RBC Capital
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019
-
Enanta Pharmaceuticals (ENTA) PT Raised to $89 at RBC Capital
-
Enanta Pharmaceuticals (ENTA) PT Lowered to $85 at RBC Capital
-
Enanta Pharmaceuticals (ENTA) PT Lowered to $90 at RBC Capital
-
Formulary Update a Net Positive for Gilead Sciences (GILD), Negative for Enanta (ENTA) - RBC
-
Enanta Pharmaceuticals (ENTA) PT Raised to $100 at RBC Capital
-
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
-
RBC Capital Downgrades Enanta Pharmaceuticals (ENTA) to Sector Perform, 'Stock Now Better Reflects HCV Royalty Growth and Pipeline Prospects'
-
RBC Capital Starts Enanta Pharmaceuticals (ENTA) at Outperform
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
-
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

